Pfizer Inc. (NYSE:PFE) Shares Bought by Sippican Capital Advisors

Sippican Capital Advisors grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 63.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,627 shares of the biopharmaceutical company's stock after purchasing an additional 26,230 shares during the period. Pfizer makes up about 1.3% of Sippican Capital Advisors' investment portfolio, making the stock its 27th largest position. Sippican Capital Advisors' holdings in Pfizer were worth $1,714,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock traded up $0.13 during trading on Friday, hitting $25.45. The company had a trading volume of 27,104,580 shares, compared to its average volume of 41,722,894. The firm has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. The business has a 50 day moving average of $23.72 and a 200 day moving average of $24.82. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PFE. Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Citigroup upped their price target on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.